Intelligent Bio Solutions Inc. INBS PHARMA
Company Overview
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
Why Investors Should Care
Revenue has grown at a 74.5% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.34.
Recent Developments
- Jun 2025 Revenue of $3.05M (-1.9% YoY); net profit $-10.57M.
- Trailing 12 Months Year-on-year growth — revenue +35.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 74.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 74.48% |
| 1 Year: | 35.80% |
Stock Price Performance
| 1 Year: | -85.76% |
| 6 Months: | -47.56% |
| 3 Months: | -10.42% |
| 1 Month: | +8.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.90 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 74.5% over 5 years.
CONS
- Trading 88.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INBS Intelligent Bio Solutions Inc. PHARMA | 2.15 | -0.25 | $7.13M | 0.00% | - | - | 74.48% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 34.29K | - | - | 192.50K | 311.32K | 356.68K | 457.06K | 796.09K | 764.06K | 823.80K | 872.29K | 607.49K | 728.87K | 1.11M | 896.77K | 1.06M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 244.04K | 33.05K | 232.33K | 199.25K | 178.49K | 346.80K | 223.11K | 341.37K | 518.29K | 459.74K | 535.38K |
| Operating Income | -1.70M | -28.82K | - | -663.00K | -917.33K | -3.14M | -1.44M | -3.47M | -1.34M | -1.22M | -2.13M | -6.54M | -2.53M | -1.99M | -2.95M | -2.73M | -2.26M | -2.56M | -3.00M | -2.64M | -2.95M |
| Net Income | -1.84M | -112.59K | -1.84M | -1.07M | -1.98M | -3.13M | -1.43M | -3.46M | -1.34M | -1.21M | -420.60K | -6.34M | -2.43M | -1.97M | -2.98M | -2.69M | -2.25M | -2.54M | -2.98M | -2.68M | -2.86M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -1.62 | -5.56 | -68.67 | -12.48 | -2.07 | -1.43 | -0.70 | -4.96 | -4.41 | -0.35 | -2.82 | -1.80 |
| R&D Expense | 494.67K | - | - | - | 341.82K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Revenue | 188.74K | 1.98M | 437.15K | 1.26M | 3.11M | 3.05M |
| Gross Profit | - | - | - | 326.67K | 1.43M | 1.25M |
| Operating Income | -2.86M | -5.57M | -8.34M | -12.60M | -10.28M | -10.64M |
| Net Income | -3.16M | -7.04M | -8.31M | -10.63M | -10.16M | -10.57M |
| Diluted EPS | - | - | -11.33 | -127.00 | -6.38 | -2.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Apr 2024 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.48M | 21.86M | 12.35M | 10.35M | - | 13.78M | 8.25M |
| Current Assets | - | - | - | 10.87M | 3.86M | - | 8.53M | 4.14M |
| Cash & Equivalents | - | 427.27K | 12.57M | 8.24M | 1.54M | - | 6.30M | 1.02M |
| Inventory | - | - | - | 0 | 979.91K | - | 777.54K | 635.22K |
| Receivables | - | - | - | 0 | 293.86K | - | 429.70K | 594.61K |
| Total Liabilities | - | 7.69M | 6.85M | 5.81M | 6.67M | - | 5.60M | 5.44M |
| Current Liabilities | - | 7.69M | 3.68M | 4.66M | 5.88M | - | 5.45M | 5.35M |
| Long Term Debt | - | - | - | - | 402.86K | 1.65M | - | - |
| Total Debt | - | - | - | 0 | 1.34M | - | 871.44K | 281.81K |
| Total Equity | -3.98M | -5.19M | 15.06M | 6.62M | 3.80M | - | 8.33M | 3.00M |
| Shares Outstanding | - | - | - | 6.20K | 19.42K | - | 345.60K | 732.34K |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -498.62K | -11.30M | -3.36M | -7.38M | -9.57M | -9.68M |
| Investing Cash Flow | -14.00K | - | -880.22K | -694.14K | -221.43K | -231.84K |
| Financing Cash Flow | 733.86K | 23.40M | - | 1.44M | 14.56M | 4.60M |
| Capital Expenditure | - | - | - | - | -221.43K | -231.84K |
| Free Cash Flow | - | - | - | - | -9.79M | -9.91M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 26.0% | 45.8% | 40.8% |
| Operating Margin % | -1,513.7% | -281.4% | -1,907.1% | -1,002.1% | -330.5% | -348.7% |
| Net Margin % | -1,676.2% | -355.3% | -1,900.1% | -845.9% | -326.4% | -346.2% |
| ROE % | 61.0% | -46.7% | -125.4% | -279.9% | -121.9% | -352.7% |
| ROCE % | 54.8% | -30.7% | -108.4% | -281.7% | -123.5% | -367.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 4.26% | 141.40K | $275.72K |
| 2 | Geode Capital Management, LLC | 0.63% | 20.84K | $40.64K |
| 3 | Vanguard Capital Management LLC | 0.18% | 5.81K | $11.33K |
| 4 | UBS Group AG | 0.17% | 5.74K | $11.18K |
| 5 | Vanguard Fiduciary Trust Co | 0.12% | 3.96K | $7.72K |
| 6 | Tower Research Capital LLC (TRC) | 0.10% | 3.28K | $6.40K |
| 7 | Osaic Holdings Inc. | 0.01% | 200 | $390 |
| 8 | Barclays Plc | - | 142 | $276 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INBS
Intelligent Bio Solutions grows to 502 customers as net loss widens to $12.5M - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNTDI3TmZWTWF0UEdHVlNJZTFpaFF1Z3ZkYTNKSkFISXdqTVB5dnd5NC05TFJBRmNhSng5M0lwTUhud0I0VTJEcjI1cXYyVHRLMkdaMzlJOEtvcmkwTEZuS0FBVWVjSzFuRVoyM3JEWGpZQmJsaUNhNUN1V3k3bEVFZ3dEUDRqR19HZXlvTk…
INBS Stock Draws Traders As FDA 510(k) Milestones Pile Up - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPcXNyejM1RVl3Vl85RzJwMllqR2JvRUVkTkJPTWcxR1BzT2RvbzZ4LUFBaHFDSDg0VmQ2SnF5TzUzTjRSWG1ZRW4wZFJxSU5LUlNWX0JxQWsxZzI5dHg3U0lWR1l1R1VoWm9jU3NVV0FGQno4NFZNb0hYVDdYcEtNakFWUEM0N005T1E?oc…
INBS Stock Reverses Early Gains After First Shipment of Drug Screening Readers Under Syrma Johari MedTech Partnership - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNZzhtUWxxa2RLdjA5Q0lJMEx4SmxnV2lmWXpvelJuNm0xYjQ4RmN5QlY4Nmt4R2dDZFpMSkZhUFhRS1Q1ZG14UUZDRjJabmR6cURfTDBEQUQwaWx4RVIzVVdnalZvQkh5dFNBUU5QaWZaUVU0UTVZRjVVTkFIUXdVckdHZkpRWHpINjZhOH…
INBS Stock Steadies As FDA Milestones And Revenue Growth Stack Up - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQNDdDVFFaTjVXX3JjbFk1bGpDR0RXQTJOX3dteG9uVFhfUFpmMFZaQXpoNnFGckp6WUVFTE4yMUVacU5sWnVHSW0wZW1ZWTRWbmhQaDQ1US1qRkxvZUwwZmpLVE1TWGR6eUVTR04zNkVQWmN5RlhTZktIMldFNk9aOGxocDhpSEhI?oc=5"…
INBS - Intelligent Bio Solutions Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBOcjhRWG1mZHJvV3RCWG1hQ2ViUDd4Nk1PMDJLenpBbjRLaWUyV1hoYW5sNWF3N0hFdVZCU2hQUnlGcWl6U1E?oc=5" target="_blank">INBS - Intelligent Bio Solutions Inc Stock Price and Quote</a> &nbs…
Intelligent Bio Solutions Revenue Rises 38% to $4.2 Million in Fiscal 2026 - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPSzF0QzhjUmtmLXJiR214V2MwbkhnVUMzelVnWXlTQ2xhY1JmRmNJYWNNUHh2UW9VZG5qck02VFV0eWw0bThyZ09UV2FGd0VkS2FETmVZY3FWOWNwbWVfUnp4NlhDanA2eTYzSWU5dG5DZ2trOXVEekNnM2lpeFNnSlpBWUx3WDM1cXkyN0…
INBS — Frequently Asked Questions
What is the current share price of Intelligent Bio Solutions Inc. (INBS)?
As of 2026-09-19 21:16 PDT, Intelligent Bio Solutions Inc. (INBS) trades at $2.15 on NasdaqCM. Its 52-week range is $1.55 to $18.80.
What is the market capitalisation of INBS?
Intelligent Bio Solutions Inc. (INBS) has a market capitalisation of $7.13M on NasdaqCM.
What is the P/E ratio of INBS?
INBS trades at a trailing price-to-earnings (P/E) ratio of -0.25. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.03.
Is INBS a good stock to buy?
This page provides a data-driven analysis of Intelligent Bio Solutions Inc. (INBS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.